Center of Nanotechnology for Treatment, Understanding, *

纳米技术治疗、理解中心，*

• 批准号: 7499926
• 负责人: SADIK ESENER
• 金额: $ 5.81万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-30 至 2010-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7499926
• 关键词: Achievement; Address; Bacteriophages; Biotechnology; Blood Circulation; CCNE1 gene; California; Cancer Center; Cells; Complex; Computing Methodologies; Decision Making; Development; Devices; Diagnosis; Diagnostic; Drug Delivery Systems; Endothelial Cells; Engineering; Facility Construction Funding Category; Goals; Homing; Image; Immune system; In Situ; In Vitro; Individual; Institutes; Knockout Mice; Libraries; Malignant Neoplasms; Marketing; Membrane; Methods; Modeling; Monitor; Nanotechnology; PAWR gene; Participant; Penetration; Peptides; Plasma; Plasma Proteins; Play; Production; Property; Proteome; Proteomics; Research; Research Personnel; Reticuloendothelial System; Role; Scientist; Site; System; Technology; Therapeutic; Therapeutic Agents; Time; Tissues; Toxic effect; Travel; Tumor Tissue; Universities; base; design; improved; in vivo; inhibitor/antagonist; macrophage; nanodevice; nanoparticle; nanoscale; nanosensors; neoplastic cell; novel; particle; programs; response; targeted delivery; therapeutic target; tumor; tumor progression; uptake

The Center of Excellence of NANOtechnology for Treatment, Understanding, and Monitoring of Cancer (NANO-TUMOR) has been established to perfect a practical nanotechnology base to diagnose, treat, and monitor cancers. Our goal is the development, of a multi-functional "smart mothership" platform that will: (1) evade the reticuloendothelial system and immune system, while attaching specifically to the tumor and its vasculature; (2) assemble a multi-functional complex at the tumor site; (3) deliver payloads of both nanosensors and therapeutics that are activated in situ. The NANO-TUMOR Center has brought together a team of investigators from the University of California, San Diego, Santa Barbara, Irvine, and Riverside campuses, the Burnham Institute and NanoBioNexus. The NANO-TUMOR Center research program is comprised of six interacting projects, each utilizing newly developed and unique technologies that when integrated together will lead to the realization of our goal. The six projects focus on (1) the production of tumor-targeted, non-toxic nanoparticles, (2) the development of a nanoporous micro-platform carrying nanosensors, imaging and therapeutic agents, (3) the creation of tumor-directed amplification systems for sensing and drug delivery, (4) the construction of devices for tumor molecule purification and characterization at a nanoscale level, (5) the application of new computational methods for longitudinal monitoring and analyses of tumor progression and response to therapy, and (6) the in situ assembly and delivery of targeted therapeutics with a smart nanotechnology platform. The Center has been organized using a novel, engineering-type decision and workflow model: Multiple approaches have been proposed to address each project, with go/no go decisions made based on achievement of milestones. The NANOTUMOR project leaders have previously founded more than 20 successful biotechnology companies, with a total market value of over two billion dollars, evidence of their ability to move discoveries to useful applications in the marketplace. The intent of the NANO-TUMOR Center to develop clinically useful platforms is also demonstrated by the strategic role that clinicians from the UCSD Cancer Center, and participants from major corporations (General Electric, Honeywell, Nanogen, Enterprise) will play in evaluating the research.

建立了癌症治疗、理解和监测纳米技术卓越中心(纳米肿瘤)，以完善诊断、治疗和监测癌症的实用纳米技术基地。我们的目标是开发一种多功能的“智能母舰”平台，它将：(1)避开网状内皮系统和免疫系统，同时专门附着于肿瘤及其血管系统；(2)在肿瘤部位组装多功能复合体；(3)提供可在原位激活的纳米传感器和治疗药物的有效载荷。纳米肿瘤中心汇集了来自加州大学圣地亚哥分校、圣巴巴拉分校、欧文分校和河滨分校、伯纳姆研究所和NanoBioNexus的研究团队。纳米肿瘤中心研究计划由六个相互作用的项目组成，每个项目都利用了新开发的独特技术，当这些技术整合在一起时，将导致我们目标的实现。这六个项目侧重于(1)生产针对肿瘤的无毒纳米颗粒，(2)开发携带纳米传感器、成像和治疗剂的纳米多孔微平台，(3)创建用于传感和药物输送的肿瘤定向放大系统，(4)建造纳米水平的肿瘤分子纯化和表征设备，(5)应用新的计算方法对肿瘤的进展和治疗反应进行纵向监测和分析，以及(6)利用智能纳米技术平台就地组装和输送靶向治疗药物。该中心采用了一种新颖的工程型决策和工作流程模型：提出了多种方法来处理每个项目，并根据里程碑的完成情况做出了进行或不进行的决定。NANOTUMOR项目负责人此前创建了20多家成功的生物技术公司，总市值超过20亿美元，这证明了他们有能力将发现转化为市场上有用的应用。UCSD癌症中心的临床医生和来自大公司(通用电气、霍尼韦尔、Nanogen、Enterprise)的参与者将在评估这项研究中发挥战略作用，这也证明了纳米肿瘤中心开发临床有用平台的意图。